TD Waterhouse Canada Inc. Has $3.35 Million Holdings in Illumina, Inc. $ILMN

TD Waterhouse Canada Inc. raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 263.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,215 shares of the life sciences company’s stock after acquiring an additional 13,205 shares during the period. TD Waterhouse Canada Inc.’s holdings in Illumina were worth $3,349,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Elyxium Wealth LLC acquired a new stake in Illumina during the 4th quarter worth approximately $25,000. Fiduciary Financial Advisors acquired a new position in Illumina in the 2nd quarter valued at $26,000. Keating Financial Advisory Services Inc. acquired a new position in Illumina in the 2nd quarter valued at $32,000. Quarry LP bought a new position in Illumina during the 3rd quarter worth $32,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Illumina during the 4th quarter worth $33,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,062,465 shares of company stock worth $436,589,802. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

ILMN opened at $218.22 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The firm has a market cap of $32.95 billion, a P/E ratio of 40.71, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46. The business’s fifty day moving average is $199.16 and its 200-day moving average is $160.04.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ILMN. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a research report on Monday, August 31st. Royal Bank Of Canada raised their price target on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, Leerink Partners increased their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $191.31.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.